GlassScriptPhysician profile
Sarah Manitsas
NPI 1790802155
$2,982.82
in general payments reported to CMS, 2019-2025
24 companies · $617 in 2025
The $617 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $80.67 · 2021: $251 · 2022: $544 · 2023: $348 · 2024: $515 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,022.88 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.60 | 2019-2023 | Xifaxan, Relistor |
| Janssen Biotech, INC. | $264.17 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $200.60 | 2019-2024 | |
| Boston Scientific Corporation | $154.50 | 2019-2023 | Interject |
| Celgene Corporation | $143.73 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $137.97 | 2019-2023 | Entyvio |
| Lilly USA, LLC | $133.06 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $76.55 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $68.29 | 2025 | Zenpep |
| Allergan, INC. | $53.81 | 2019 | |
| Intra-Sana Laboratories | $52.47 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $49.83 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $44.09 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $40.74 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37.25 | 2024 | Voquezna |
| Coloplast Corp | $35.71 | 2021 | |
| Pfizer INC. | $25.60 | 2025 | |
| Redhill Biopharma INC. | $22.95 | 2021 | |
| Vivus LLC | $21.72 | 2025 | Pancreaze |
| Ucb, INC. | $18.95 | 2019 | |
| Ardelyx, INC. | $18.81 | 2023 | Ibsrela |
| Shionogi INC | $15.76 | 2019 | |
| Ethicon US, LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Manitsas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.